Business
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study. SHINE enrolled 153 adults with mild-to-moderate Alzheimer’s disease who were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months. The only way to participate in the live webcast is to register online by clicking here. The event will also be archived on the Investor Relations section of the Cognition website. Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer’s Association’s International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday. In addition, results of a meta-analysis of phosphoproteomics from the 23-patient SPARC study and the first 24 SHINE participants (SHINE-A) will be presented on Sunday, July 28. Results of proteomic analyses from this meta-analysis were recently accepted for publication in Alzheimer's & Dementia, the Journal of the Alzheimer's Association. AAIC Presentation details Sunday, July 28, 2024 (8:30a.m. - 4:15p.m. ET) 1.Abstract #95147: CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease Monday, July 29, 2024 (8:30a.m. - 4:15p.m. ET) 2.Abstract #89115: Clinical Efficacy Results from COG0201: a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease 3.Abstract #95767: Topline CSF Biomarker Outcomes from the Phase 2 Clinical Trial SHINE in Alzheimer's Patients 4.Abstract #95770: Exploratory CSF Proteomics Biomarker Outcomes of the Phase 2 Clinical Trial Shine to Assess the Effects of Ct1812 in Alzheimer’s Patients Date and Time: Monday July 29, 8:30 A.M. Webcast Details:Company management will be joined by an inve...